<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146379">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02011386</url>
  </required_header>
  <id_info>
    <org_study_id>MANGO</org_study_id>
    <nct_id>NCT02011386</nct_id>
  </id_info>
  <brief_title>Novel MRI ANd Biomarkers in GOlimumab-treated Patients With Axial Spondyloarthritis</brief_title>
  <acronym>MANGO</acronym>
  <official_title>Improved Monitoring and Prediction of Clinical Response and Disease Course During Golimumab Therapy of Patients With Axial Spondyloarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Susanne Juhl Pedersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <authority>Denmark: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study investigates different criteria for remission based on MRI and circulating
      biomarkers for inflammation, cartilage, connective tissue and bone turnover in patients with
      axial spondyloarthritis treated with Golimumab. Furthermore, the study also investigates
      factors that affect disease activity, function and participation by use of different
      questionnaires.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Fulfillment of BASDAI50 (i.e. reduction of 50%)</measure>
    <time_frame>Week 52</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in MRI assessment (score)</measure>
    <time_frame>Week 16</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Number (percentage) of patients with ASDAS response</measure>
    <time_frame>Week 16 and 52</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Axial Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <description>Treatment: Injection Golimumab 50 mg every month on the same date</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment</intervention_name>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Treatment: Injection Golimumab 50 mg every month on the same date</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with axial spondyloarthritis with moderate to high disease activity (BASDAI &gt;= 40
        mm), who are going to start treatment with tumor-necrosis-factor-alpha inhibitor.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Axial spondyloarthritis according to the ASAS classification criteria

          -  Sacroiliitis on conventional X-rays or MRI.

          -  Disease activity assessed by BASDAI &gt;40 mm despite treatment with NSAID.

          -  Clinical indication for tumor-necrosis-factor-alpha inhibitor treatment by the
             treating physician.

        Exclusion Criteria:

          -  No contraindications for tumor-necrosis-factor-alpha inhibitor

          -  No contraindications for MRI

          -  No contraindications in participation in a study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikkel Østergaard, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glostrup Hospital, University of Copenhagen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikkel Østergaard, Professor</last_name>
    <phone>+4521603865</phone>
    <email>mo@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susanne J Pedersen, MD, PhD</last_name>
    <phone>+4541431326</phone>
    <email>sjp@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Frederiksberg Bispebjerg Hospitals, Dep. of Rheumatology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bente Jensen, Consultant</last_name>
      <phone>+4538163816</phone>
      <email>Bente.Jensen.06@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital, Dep. of Rheumatology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ole R Madsen, Consultant</last_name>
      <phone>+4539773977</phone>
      <email>Ole.Rintek.Madsen@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital, Dep. of Rheumatology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital, Dep. of Radiology</name>
      <address>
        <city>Copenhagen</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lone Balding, Consultant</last_name>
      <phone>+4544884488</phone>
      <email>lone.balding@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nordsjællands Hospital Hillerød, Dep. of Rheumatology</name>
      <address>
        <city>Hillerød</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jesper Nørregaard, Consultant</last_name>
      <phone>+4548294829</phone>
      <email>Jesper.Noerregaard.02@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Køge Hospital, Dep. of Rheumatology</name>
      <address>
        <city>Køge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Stoltenberg, Consultant</last_name>
      <phone>+4556631500</phone>
      <email>mbst@regionsjaelland.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 10, 2013</lastchanged_date>
  <firstreceived_date>December 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Susanne Juhl Pedersen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Spondylitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
